Increased cortical inhibition induced by apomorphine in patients with Parkinson's disease.
The electromyographic silent period following the motor potential evoked by cortical magnetic stimulation is decreased in parkinsonian patients. In this study we investigated whether the decrease in the silent period is connected only with parkinsonian symptoms. We evaluated the effect of apomorphine (a potent and rapid dopamine-agonist) on the changes in the peripheral and central silent period in 29 patients with Parkinson's disease and in two patients affected by multisystem atrophy (MSA). Apomorphine injection was found to induce a significant improvement in the central silent period in parkinsonian patients but not in the MSA patients, suggesting a relation between the clinical parkinsonian symptoms (akinesia and rigidity) and the silent period duration. The central silent period changes after apomorphine injection could be used as an adjunctive, safe and effective diagnostic tool to assess dopamine responsiveness of parkinsonian syndromes.
Manfredi
L
L
Department of Neurology, Ospedale Valduce, Como, Italy.
Garavaglia
P
P
Beretta
S
S
Pellegrini
G
G
D000368:Aged; D000978:Antiparkinson Agents / Q000494:pharmacology*; D001058:Apomorphine / Q000494:pharmacology*; D002540:Cerebral Cortex / Q000187:drug effects* / Q000503:physiopathology*; D004574:Electromagnetic Fields; D004576:Electromyography; D019054:Evoked Potentials, Motor / Q000187:drug effects; D005260:Female; D006801:Humans; D008297:Male; D009044:Motor Cortex / Q000187:drug effects / Q000503:physiopathology; D019578:Multiple System Atrophy / Q000503:physiopathology; D010300:Parkinson Disease / Q000503:physiopathology*; D013003:Somatosensory Cortex / Q000187:drug effects / Q000503:physiopathology
D000978:Antiparkinson Agents; D001058:Apomorphine